At BioPorto Diagnostics we are always interested in expanding our antibody portfolio. If you have monoclonal antibodies that you would like to make available to researchers globally, we would be very happy to hear from you. We have a long, successful track record of in-licensing antibodies through efficient licensing procedures and development of effective commercialization paths.
- We can offer to license your unique antibody clones and provide royalties in return
- We have a state-of-the-art hybridoma cell culturing facility, which will ensure that the best quality product is produced from your hybridomas
BioPorto´s current product portfolio consists of unique antibodies within the research areas of coagulation, complement cascade, peptide hormones, and kidney diseases. BioPorto seeks to strengthen our product portfolio in these areas as well as to expand product offerings in other research and clinical spaces.